>

The Foundation Fighting Blindness, Inc. invested in Sparing Vision

Jul 14, 2017 - RelSci Data Update
Investments

Background Information:
The Foundation Fighting Blindness, Inc. provides preventions, treatments and cures for people affected by retinitis pigmentosa, macular degeneration and usher syndrome. The firm also provides provide information on retinal degenerative diseases to all who request it, in order to increase knowledge and awareness of these diseases. It has locations in Columbia, Denver, Libertyville, New York, Plano, Raleigh and Santa Monica. The company was founded on September 16, 1971 and is headquartered in Columbia, MD.
In The News:
Eloxx Pharmaceuticals Reports Third Quarter 2018 Financial and Operating Results and Provides Business Update
November 8, 2018  •  GlobeNewswire
Foundation Fighting Blindness Establishes $70 Million Fund
October 25, 2018  •  Philanthropy News Digest
Foundation Fighting Blindness Launches Retinal Degeneration Fund With More Than $70 million of Initial Funding
October 23, 2018  •  PR Newswire
The Foundation Fighting Blindness, Inc. provides preventions, treatments and cures for people affected by retinitis pigmentosa, macular degeneration and usher syndrome. The firm also provides provide information on retinal degenerative diseases to all who request it, in order to increase knowledge and awareness of these diseases. It has locations in Columbia, Denver, Libertyville, New York, Plano, Raleigh and Santa Monica. The company was founded on September 16, 1971 and is headquartered in Columbia, MD.
SparingVision SAS develops therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa. The company was founded by Jose Alain Sahel, Thierry Leveillard and Florence Allouche Ghrenassia and is headquartered in Paris, France.
In The News:
SparingVision to Present the Progress regarding Retinitis Pigmentosa's Treatment during the Annual Congress of Association for Research in Vision and Ophthalmology (ARVO)
May 2, 2018  •  Business Wire
SparingVision Participated in the 10th Annual Biotech Showcase
January 12, 2018  •  GlobeNewswire
SparingVision SAS develops therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa. The company was founded by Jose Alain Sahel, Thierry Leveillard and Florence Allouche Ghrenassia and is headquartered in Paris, France.